Also known as: Metandienone, Methandienone, 72-63-9, Dianabol, Nerobol, Metanabol
A synthetic steroid with anabolic properties that are more pronounced than its androgenic effects. It has little progestational activity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1188)
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
InChI=1S/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1
XWALNWXLMVGSFR-HLXURNFRSA-N
CC12CCC3C(C1CCC2(C)O)CCC4=CC(=O)C=CC34C
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CCC4=CC(=O)C=C[C@]34C
COZ1R7EOCC
Metandienone, Methandienone, 72-63-9, Dianabol, Nerobol, Metanabol, Metandienonum, Methandrolone, Metandienon, Metandrostenolon, Metandrostenolone, Metastenol, Nerobolettes, Protobolin, Anabolin, Andoredan, Danabol, Dianabole, Encephan, Naposim, Perbolin, Stenolon, Stenolone, Abirol, Crein, Dehydromethyltestosterone, Geabol, Anabolicum Medivet, Methylandrostenolone, 1-dehydromethyltestosterone, Compound 17309, Nsc-42722, Ciba 17309-ba, 1,2-dehydro-17-methyltestosterone, 17beta-hydroxy-17-methylandrosta-1,4-dien-3-one, 1-dehydro-17alpha-methyltestosterone, 17alpha-methyl-1-dehydrotestosterone, Testosterone, 1-dehydro-17-methyl-, 1-dehydro-17-alpha-methyltestosterone, 17-alpha-methyl-1-dehydrotestosterone, Metandienone [inn], Coz1r7eocc, Sterolon, 17-beta-hydroxy-17-alpha-methylandrostra-1,4-dien-3-one, 1-dehydro-17-methyltestosterone, Androsta-1,4-dien-3-one, 17-beta-hydroxy-17-alpha-methyl-, 17-beta-hydroxy-17-methyl-androsta-1,4-dien-3-one, Metandienone (inn), (17beta)-17-hydroxy-17-methylandrosta-1,4-dien-3-one, (8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13,17-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one, Ncgc00159415-02, Ncgc00159415-04, Methandienonum, 1-dehydro-17-.alpha.-methyltestosterone, Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17b)-, Dsstox_cid_3276, Methandrostenolonum, Dsstox_rid_76952, Dsstox_gsid_23276, .delta.'-17-methyltestosterone, Metandienonum [latin], Metandienona, Metandienona [spanish], A1-dehydromethyltesterone, Methandrostenolone [usp], Metandrostenolone [dcit], Metandienonum [inn-latin], 1-dehydro-17.alpha.-methyltestosterone, 17.alpha.-methyl-1-dehydrotestosterone, Cas-72-63-9, Ma (van), Ciba 17309 Ba, Metandienona [inn-spanish], .delta.1-17.alpha.-methyltestosterone, Delta'-17-methyltestosterone, Androsta-1, 17.beta.-hydroxy-17-methyl-, Tmv 17, Hsdb 3360, Androsta-1, 17.beta.-hydroxy-17.alpha.-methyl-, Unii-coz1r7eocc, Delta(1)-17alpha-methyltestosterone, Delta-1,17-alpha-methyltestosterone, Einecs 200-787-2, Nsc 42722, Androsta-1, 17-hydroxy-17-methyl-, (17.beta.)-, 17-.beta.-hydroxy-17-methyl-androsta-1,4-dien-3-one, 17-.beta.-hydroxy-17-.alpha.-methylandrostra-1,4-dien-3-one, Delta(sup 1)-17-alpha-methyltestosterone, Androsta-1,4-diene-3-one, 17-hydroxy-17-methyl-, (17.beta.)-, Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17beta)-, 17alpha-methyl-17beta-hydroxyandrosta-1,4-dien-3-one, Androsta-1,4-dien-3-one, 17beta-hydroxy-17-methyl-, 17-alpha-methyl-17-beta-hydroxy-1,4-androstadien-3-one, 17-hydroxy-17-methylandrosta-1,4-dien-3-one, Alpha-methyltestosterone, Dianabol (tn), Metandienone [who-dd], Methandienone [mart.], Schembl140928, Methandrostenolone [mi], Chebi:6810, Chembl1418176, Dtxsid2023276, Methandrostenolone [hsdb], Methandrostenolone [vandf], 1-dehydro-17-methyl-testosterone, Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17-beta)-, Androsta-1,4-diene-3-one, 17-hydroxy-17-methyl-, (17beta)-, Bcp10774, Nsc42722, Nsc51180, Zinc3875469, Tox21_111647, 1, 2-dehydro-17-methyltestosterone, Bbl029917, Lmst02020013, Nsc-51180, S4796, Stk801870, Akos005267170, Tox21_111647_1, Ccg-267474, Db13586, 17-.alpha.-methyl-1-dehydrotestosterone, Ncgc00159415-03, Ncgc00159415-05, 17alpha-methyl-androsta-1,4-dien-3-one, Laquo Deltaraquo '-17-methyltestosterone, Vs-09501, .delta.-1,17-.alpha.-methyltestosterone, 17-alpha-methylandrostra-1,4-dien-3-one, Laquo Deltaraquo 1-17alpha-methyltestosterone, Methandrostenolone 100 Microg/ml In Methanol, D00389, Ab01332687-02, Methandrostenolone 100 Microg/ml In Acetonitrile, 17-hydroxy-17-methylandrosta-1,4-dien-3-one #, Q417194, 17beta-hydroxy-17-methyl-androsta-1,4-dien-3-one, Laquo Deltaraquo (sup1)-17alpha-methyltestosterone, Androsta-1,4-dien-3-one, 17alpha-methyltestosterone, 17beta-hydroxy-17-methylandrosta-1,4-dien-3-one, 98%, 17beta-hydroxy-17alpha-methyl-androsta-1,4-dien-3-one, 17beta-hydroxy-17alpha-methylandrosta-1,4-dien-3-one, 17-hydroxy-17-methyl-(17beta)-androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-(17beta)-androsta-1,4-diene-3-one, Androsta-1,4-dien-3-one, 17.alpha.-hydroxy-17-methyl-, 17.beta.-hydroxy-17-methylandrosta-1,4-dien-3-one, 17-hydroxy-17-methylandrosta-1,4-dien-3-one (acd/name 4.0), Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17.alpha.)-, 17beta-hydroxy-17-methylandrosta-1,4-dien-3-one, >=99.0% (hplc), 17beta-hydroxy-17-methylandrosta-1,4-dien-3-one, Analytical Standard, (1s,3as,3br,9ar,9bs,11as)-1-hydroxy-1,9a,11a-trimethyl-1h,2h,3h,3ah,3bh,4h,5h,7h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-one, (8r,10r,13s,17s)-17-hydroxy-10,13,17-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one, (9s,10r,13s,14s,17s)-17-hydroxy-10,13,17-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one, Methandienone Solution, 1.0 Mg/ml In 1,2-dimethoxyethane, Ampule Of 1 Ml, Certified Reference Material
2005-03-26
Anabolic Steroids
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
A two compartment, double-blind, randomized, parallel study was performed comparing methandrostenolone with placebo in the treatment of osteoporosis. The duration of the study was 24 mo. Dependent parameters included total body calcium (TBCa), measured by neutron activation analysis: bone mineral content of the radius (BMC), measured by photon absorptiometry; and total body potassium (TBK), measured by total body counting. A significant increase in TBK occurred in the treated group, primarily in the first 6 mo; thereafter the TBK remained fairly constant. No significant changes in bone mass occurred, except the 6 mo TBCa measurement increased by 11 grams for the methandrostenolone group and decreased by 6 grams for the placebo group (p = .05). Other evidence also suggests that anabolic steroids may not produce sustained uncoupling of bone formation and bone resorption in osteoporosis. If methandrostenolone is capable of producing an increment in bone mass in osteoporosis, it was not readily observable with the sensitivity of the techniques employed in this study
PMID:7026971 Aloia JF et al; Metabolism 30 (11): 1076-9 (1981)
VET: orally, to increase nitrogen retention and increase serum protein values aiding in tissue repair and decrease healing time after surgery, burns, or skin grafts. Also in geriatric states, debilitation, and after chronic infections. As aid in calcium retention in senile, corticosteroid induced, or idiopathic osteoporosis.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 346
Use of anabolic steroids by athletes is not recommended. Objective evidence is conflicting and inconclusive as to whether these medications significantly increase athletic performance by increasing muscle strength. Weight gains reported by athletes are due in part to fluid retention, which is a potentially hazardous side effect of anabolic steroid therapy. The risk of other unwanted effects, such as testicular atrophy and suppression of spermatogenesis in males; menstrual disturbances and virilization, such as deepening of voice, development of acne, and unnatural growth of body hair in females; peliosis hepatis or other hepatotoxicity; and hepatic cancer outweigh any possible benefit received from anabolic steroids and make their use in athletes inappropriate. /Anabolic Steroids/
Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 140
Hepatocellular carcinoma has been associated rarely with long-term, high-dose anabolic steroid therapy. /Anabolic Steroids/
Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141
Hepatic neoplasms have been associated rarely with long-term, high-dose anabolic steroid therapy. /Anabolic Steroids/
FDA Pregnancy Category X. /CONTRAINDICATED IN PREGNANCY. Studies in animals and or humans, or investigational or post-marketing reports, have demonstrated positive evidence of fetal abnormalities or risk which clearly outweighs any possible benefit to the patient./
For more Drug Warnings (Complete) data for METHANDROSTENOLONE (19 total), please visit the HSDB record page.
Anabolic Agents
